Editorials
Refining treatment for the men who need it: lessons from the PIVOT trial
Translational Andrology and Urology
2013;
2
(2)
:82-84
.
(16 July 2013)
Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?
Translational Andrology and Urology
2013;
2
(2)
:85-88
.
(16 July 2013)
Immunotherapy in renal cell cancer: the more the merrier?
Translational Andrology and Urology
2013;
2
(2)
:89-91
.
(16 July 2013)
Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
Translational Andrology and Urology
2013;
2
(2)
:92-93
.
(16 July 2013)
Original Articles
Treatment of failed vasectomy reversal using a microsurgical two-layer anastomosis technique
Translational Andrology and Urology
2013;
2
(2)
:94-98
.
(16 July 2013)
VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis
Translational Andrology and Urology
2013;
2
(2)
:99-105
.
(16 July 2013)
Review Article
Exogenous testosterone: a preventable cause of male infertility
Translational Andrology and Urology
2013;
2
(2)
:106-113
.
(16 July 2013)
Research Highlights
Tivozanib: a novel VGFR inhibitor for kidney cancer
Translational Andrology and Urology
2013;
2
(2)
:114-116
.
(16 July 2013)
Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
Translational Andrology and Urology
2013;
2
(2)
:117-118
.
(16 July 2013)
Enzalutamide: the emperor of all anti-androgens
Translational Andrology and Urology
2013;
2
(2)
:119-120
.
(16 July 2013)
